• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer.在MYC驱动的卵巢癌中联合使用PARP和CDK4/6抑制剂。
EBioMedicine. 2019 May;43:9-10. doi: 10.1016/j.ebiom.2019.04.009. Epub 2019 Apr 9.
2
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.联合抑制PI3K和PARP对治疗具有野生型PIK3CA基因的卵巢癌细胞有效。
Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.
3
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.CDK4/6抑制剂在转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌中的应用探讨
Oncology (Williston Park). 2018 Oct 15;32(10):513-5.
4
When in the treatment continuum to use PARP inhibition in ovarian cancer.在卵巢癌的治疗过程中何时使用聚（ADP-核糖）聚合酶（PARP）抑制剂。
Clin Adv Hematol Oncol. 2021 Feb;19(2):84-86.
5
The current status of PARP inhibitors in ovarian cancer.PARP抑制剂在卵巢癌中的现状
Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
6
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.选择 CDK4/6 抑制剂在激素受体阳性晚期乳腺癌中的最佳位置-SONIA 研究：一项随机对照试验的研究方案。
BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1.
7
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.MYC 状态可作为卵巢癌细胞对奥拉帕利和帕博西尼协同反应的决定因素。
EBioMedicine. 2019 May;43:225-237. doi: 10.1016/j.ebiom.2019.03.027. Epub 2019 Mar 18.
8
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?PARP抑制剂在卵巢癌治疗中的地位如何？
Curr Oncol Rep. 2016 May;18(5):29. doi: 10.1007/s11912-016-0515-z.
9
CDK4/6 inhibitors in luminal breast cancer.
Lancet Oncol. 2015 Jan;16(1):2-3. doi: 10.1016/S1470-2045(14)71188-X. Epub 2014 Dec 16.
10
Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.卵巢癌中新型聚ADP核糖聚合酶抑制剂联合策略
Curr Opin Obstet Gynecol. 2018 Feb;30(1):7-16. doi: 10.1097/GCO.0000000000000428.

引用本文的文献

1
PARP inhibitors: enhancing efficacy through rational combinations.PARP 抑制剂：通过合理联合增强疗效。
Br J Cancer. 2023 Oct;129(6):904-916. doi: 10.1038/s41416-023-02326-7. Epub 2023 Jul 10.
2
A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.一种新型 CDK4/6 和 PARP 双重抑制剂 ZC-22 有效抑制乳腺癌和卵巢癌的肿瘤生长并提高顺铂治疗的反应。
Int J Mol Sci. 2022 Mar 7;23(5):2892. doi: 10.3390/ijms23052892.
3
C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.C/EBPβ 通过增强同源重组修复促进高级别浆液性卵巢癌对多聚（ADP-核糖）聚合酶抑制剂的耐药性。
Oncogene. 2021 Jun;40(22):3845-3858. doi: 10.1038/s41388-021-01788-4. Epub 2021 May 8.
4
Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6.外泌体 miR-21-5p 通过调节 CDK6 促进卵巢癌进展。
Hum Cell. 2021 Jul;34(4):1185-1196. doi: 10.1007/s13577-021-00522-2. Epub 2021 Apr 3.
5
Prognostic gene expression signature for high-grade serous ovarian cancer.用于高级别浆液性卵巢癌的预后基因表达特征。
Ann Oncol. 2020 Sep;31(9):1240-1250. doi: 10.1016/j.annonc.2020.05.019. Epub 2020 May 28.

本文引用的文献

1
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.MYC 状态可作为卵巢癌细胞对奥拉帕利和帕博西尼协同反应的决定因素。
EBioMedicine. 2019 May;43:225-237. doi: 10.1016/j.ebiom.2019.03.027. Epub 2019 Mar 18.
2
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.奥拉帕利和 α 特异性 PI3K 抑制剂阿培利司治疗上皮性卵巢癌患者：一项剂量递增和剂量扩展的 1b 期试验。
Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.
3
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.通过细胞周期检验点抑制，可以克服 PARP 抑制剂耐药的复制叉稳定恢复机制。
Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
4
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.抑制BET活性可使同源重组功能正常的癌症对PARP抑制敏感。
Sci Transl Med. 2017 Jul 26;9(400). doi: 10.1126/scitranslmed.aal1645.
5
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in mutant cancers.PARP与MEK抑制剂的合理联合疗法利用了突变癌症中的治疗缺陷。
Sci Transl Med. 2017 May 31;9(392). doi: 10.1126/scitranslmed.aal5148.
6
A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.Myc 活性特征可预测 Myc 相关癌症的不良临床结局。
Cancer Res. 2017 Feb 15;77(4):971-981. doi: 10.1158/0008-5472.CAN-15-2906. Epub 2016 Dec 6.
7
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.亚致死浓度的17-AAG可抑制同源重组DNA修复，并增强HR功能正常的卵巢癌细胞对卡铂和奥拉帕尼的敏感性。
Oncotarget. 2014 May 15;5(9):2678-87. doi: 10.18632/oncotarget.1929.
8
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.联合使用 PI3K 抑制剂和 PARP 抑制剂可为 BRCA1 相关乳腺癌提供有效的治疗方法。
Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22.
9
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.c-MYC基因扩增及8号染色体多倍体在次优切除的晚期上皮性卵巢癌中的预后相关性：一项妇科肿瘤学组研究
Gynecol Oncol. 2009 Sep;114(3):472-9. doi: 10.1016/j.ygyno.2009.05.012. Epub 2009 Jun 12.
10
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.缺氧诱导E2Fs下调BRCA1表达。
Cancer Res. 2005 Dec 15;65(24):11597-604. doi: 10.1158/0008-5472.CAN-05-2119.

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer.

作者信息

Konecny Gottfried E

机构信息

Division of Hematology/Oncology, Department of Medicine, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Los Angeles, CA 90095, USA.

出版信息

EBioMedicine. 2019 May;43:9-10. doi: 10.1016/j.ebiom.2019.04.009. Epub 2019 Apr 9.

DOI:10.1016/j.ebiom.2019.04.009
PMID:30979685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6557782/
Abstract
摘要